

**WEPL01 Building bridges from scientific innovation to implementation**

Plenary Session

**Venue:** Hall 12

**Time:** 08:45-10:30

**Chair:** Sandra Granger, Spouses of Caribbean Leaders Action Network, Guyana

**Introduction address**

*H. Abbasi, Chevron Corporation, United States*

**ViiV stigma award**

*D. Waterhouse, ViiV Healthcare, United Kingdom*

**The newest science in the search for a cure and vaccine**

*B. Jones, Weill Cornell Medicine and The George Washington University, United States*

**ART 2018 – Moving into the integrase era**

*P. Cahn, Fundacion Huesped, Argentina*

**Differentiated models of prevention**

*N. Kilonzo, National AIDS Control Council (NACC), Kenya*

**WEAX01 AIDS 2018 Co-chairs' choice**

Oral Abstract Session

**Venue:** Hall 12

**Time:** 11:00-12:30

**Co-Chairs:** Linda-Gail Bekker, Desmond Tutu HIV Centre, South Africa  
Peter Reiss, ,

**Engagement in methadone maintenance therapy associated with less time with plasma HIV-1 RNA viral load above 1500 copies/mL among a cohort of HIV-positive people who use drugs in Vancouver, Canada**

*B. Barker, C. Fairgrieve, K. Ahamad, T. Kerr, J. Shoveller, J. Montaner, E. Wood, M.-J. Milloy  
Canada*

**Universal test and treat (UTT) versus standard of care for access to antiretroviral therapy in HIV clients: The MaxART stepped-wedge randomized controlled health systems trial in Swaziland**

*S. Khan, D. Spiegelman, F. Walsh, S. Mazibuko, M. Pasi, B. Chai, R. Reis, K. Mlambo, W. Delva, G. Khumalo, M. Zwane, Y. Fleming, E. Mafara, A. Hettema, C. Lejeune, T. Bärnighausen, V. Okello  
Swaziland*

**Men's HIV risk profiles in South African DREAMS sites: Using latent class analysis for more strategic, context-specific programming and evaluation**

*A. Gottert, C.J. Heck, S. Mathur, J. Pulerwitz  
United States*

**Risk of HIV transmission through condomless sex in MSM couples with suppressive ART: The PARTNER2 Study extended results in gay men**

*A. Rodger, V. Cambiano, T. Bruun, P. Vernazza, S. Collins, G.M. Corbelli, O. Degen, V. Estrada, A.M. Geretti, A. Beloukas, A.N. Phillips, J. Lundgren, for the PARTNER Study Group  
United Kingdom*

**Impact of prevention and treatment interventions on population HIV incidence: Primary results of the community-randomized Ya Tsie Botswana prevention project**

*M.J. Makhema, K. Wirth, M. Pretorius Holme, T. Gaolathe, M. Mmalane, E. Kadima, U. Chakalisa, K. Manyake, A. Mbikiwa, S. Simon, R. Letlhogile, K. Mukokomani, E. van Widenfelt, S. Moyo, S. Bennett, J. Leidner, R. Lebelonyane, M.G. Alwano, K. Powis, S. Dryden-Peterson, C. Kgathi, V. Novitsky, J. Moore, P. Bachanas, W. Abrams, L. Block, S. El-Halabi, T. Marukutira, L.A. Mills, H. Bussmann, L. Okui, O. John, R. Shapiro, V. DeGruttola, Q. Lei, R. Wang, E. Tchetgen Tchetgen, M. Essex, S. Lockman  
Botswana*

**SEARCH community cluster randomized study of HIV "test and treat" using multi- disease approach and streamlined care in rural Uganda and Kenya**

*D. Havlir, E. Charlebois, L. Balzer, T. Clark, D. Kwarisiima, J. Ayieko, J. Kabami, N. Sang, T. Liegler, G. Chamie, C. Camlin, K. Kadede, A. Mucunguzi, V. Jain, T. Ruel, S. Shade, E. Ssemondo, D. Byonanebye, F. Mwangwa, A. Owaraganise, W. Ollilo, D. Black, K. Snyman, R. Burger, M. Getahun, J. Achando, B. Awuonda, H. Nakato, J. Kironde, H. Thirumurthy, C. Koss, L. Brown, C. Marquez, J. Schwab, G. Lavoy, A. Plenty, E. Mugoma Wafula, P.- Omanyia, J. Rooney, M. Bacon, M. van der Laan, C. Cohen, E. Bukusi, M. Petersen, M. Kanya, SEARCH Collaboration  
United States*

**WEAB01 Keep your eyes on OIIs and STIs**

Oral Abstract Session

**Venue:** Hall 10

**Time:** 11:00-12:30

**Co-Chairs:** Margaret Borok, University of Zimbabwe, Zimbabwe  
Sam Phiri, Lighthouse Trust Clinic, Malawi

**Evaluation of a national cryptococcal antigen screening program for HIV-infected patients in Uganda: A cost-effectiveness modeling analysis**

*R. Rajasingham, D. Meya, G. Greene, A. Jordan, T. Chiller, D. Boulware, B. Larson  
United States*

**HIV-associated central nervous system infections in Indonesia: A cohort study examining etiology, presentation and outcome**

*D. Imran, R. Estiasari, K. Maharani, S. Sucipto, D.C. Lestari, R. Eddy, E. Yuniastuti, T. Harjono, D. Oei, I.S. Timan, D. Wulandari, R. Wahyuningsih, A. Bahri, A. Kurniawan, R. Mulyadi, A. Karuniawati, U.A. Jaya, D. Safari, A. van Laarhoven, B. Alisjahbana, S. Dian, L. Chaidir, A.R. Ganiem, D.N. Lastri, K.S.A. Myint, R. van Crevel  
Indonesia*

**Burden of sexually transmitted infections and prevalence of HIV among key population individuals presenting with STIs in Nepal**

*D.P. Bhandari, K.P. KC, H. Subhani, R.K. Shrestha, B.M. Shrestha, P.K. Thakur, I. Adhikary, B. Shrestha, M. Avery, K. Bam  
Thailand*

**Natural history of anogenital HPV infection and related disease among HIV-positive men: Findings from a Cohort Study in South Africa**

*A. Chikandiwa, P.T. Pisa, C. Tamalet, E.E. Muller, R. Kularatne, P. Michelow, M.F. Chersich, P. Mayaud, S. Delany-Moretlwe  
South Africa*

**Kaposi disease in HIV-infected patients with suppressed HIV viremia: The experience of the French national multidisciplinary committee ONCOVH**

*R. Palich, M. Veyri, M.-A. Valantin, A.-G. Marcelin, F. Boué, A. Guihot, C. Solas, H. Ait-Mohand, V. Martinez, I. Poizat-Martin, D. Costagliola, J.-P. Spano, C. Katlama, ONCOVH Study Group  
France*

**Kaposi sarcoma incidence remains unchanged among African American males in the Southern United States: U.S. Cancer Statistic Data, 2000-2014**

*E. Chiao, T. Aaron, Y. Dong, R. Kathryn, J. Kramer, W. Donna  
United States*

**WEAC01 The new high risk populations: Who are they?**

Oral Abstract Session

**Venue:** Elicium 1

**Time:** 11:00-12:30

**Chair:** Selvamuthu Poongulali, YRGCARE, India

**Reaching out to hidden population in Malaysia: MSMs, transgender and sex workers in Muslims majority setting where sex is a crime**

*Y. Md Yusralhakim  
Malaysia*

**Geosocial networking app use among men who have sex with men in China: Findings from the T2T study**

*H. Zou, X. Meng, Y. Lu, Z. Wang, T. Jia, H. Yin, Z. Luo, Y. Ding, W. Chen, S. Huang, H. Zheng, B. Yang, A. Grulich, The T2T Study  
China*

**Extended risk network testing to find HIV cases among key populations in Ukraine: Predicting recruitment of HIV-positive clients with machine learning**

*P. Smyrnov, Y. Sereda, I. Sazonova, K. Boiko, Y. Kuznetsova, K. Slobodianiuk, O. Denisiuk, S.R. Friedman*  
Ukraine

**When and why? Timing and determinants of post-migration HIV acquisition among sub-Saharan immigrants in France**

*A. Gosselin, A. Ravalihasy, J. Pannetier, F. Lert, A. Desgrées du Loû, Parcours Study Group*  
France

**Patterns of substance use among young men who have sex with men and their associations with HIV risk behavior and sexually transmitted infections**

*M. Newcomb, G. Swann, B. Mustanski*  
United States

**WEAE01 Reaching men: Yes we can!**

Oral Abstract Session

**Venue: Hall 11A**

**Time: 11:00-12:30**

**Co-Chairs:** Godfrey Musuka, ICAP, Zimbabwe  
Helen Ayles, Zambart, Zimbabwe

**Multiple disease screening to destigmatize HIV testing and increase identification of persons living with HIV in Kisumu, Kenya**

*K. Ndede, D. Naitore, F. Lugalia, C. Wells, B. Senyana, J. Otieno, R. Fayorse, M. Hawken, E. Abrams*  
Kenya

**Cracking the code to increase men's uptake of HIV testing: Providing convenient and confidential outreach HIV testing services through mobile clinics**

*E. Geoffroy, N. Khozomba, J. Jere, E. Schell, T. Schafer, J. Goldman, K. Kabwere*  
United States

**Engaging young men in health care and HIV testing: The SHAZ! HUB youth drop-in-centre**

*M.S. Dunbar, G. Chapwanya, G. Kumalo-Sakutukwa, I. Mahaka, A. Mpakati, M. Lightfoot*  
Zimbabwe

**Home-based testing identifies more previously undiagnosed older men than mobile testing in Botswana**

*M. Roland, L. Block, P. Bachanas, M.G. Alwano, W. Abrams, K. Wirth, T. Gaolathe, J. Makhema, M. Mmalane, S. Lockman, S. El-Halabi, J. Moore*  
Botswana

**Male engagement works to improve HIV services uptake among men**

*T.A. Lekhotsa, B. Oguntoyinbo, M. Mputsoe, M.G. Mefane, V. Tukei, E. Tumbare*  
Lesotho

**WEAD01 Justice on the margins: Legal strategies to address barriers to HIV services**

Oral Abstract Session

**Venue: Hall 11B**

**Time: 11:00-12:30**

**Co-Chairs:** Richard Elliott, Canadian HIV/AIDS Legal Network, Canada  
Annabel Raw, Southern Africa Litigation Centre, South Africa

**Innovative paralegal and advocacy program enhancing access to justice and harm reduction services in Mombasa county**

*H. Tayab, A. Badhrus, F. Jeneby, M. Fahmy, F. Abdulrahman, M. Handulle*  
Kenya

**Paralegal community in the epidemic of injustice: The role of paralegals from drug users communities in the fulfillment of drug users rights**

*A. Qisthi*  
Indonesia

**Street lawyers from the harm reduction project at the ARF and their contribution to the fight for the right to health of PWUD and people living with HIV**

*M. Malyshev*  
Russian Federation

**A novel method of working with judges to build their capacity on HIV and human rights in Africa**

*D. Patel, P. Patel, A. Saha, C. Grant, D. Owolabi*  
UNDP

**Assessing HIV key populations' participation in seeking justice to test the effectiveness of human rights redress mechanism in Indonesia**

*A. Wirya, F. Aotari*  
Indonesia

**WEAE02 Tough choices, smart decisions, maturing responses**

Oral Abstract Session

**Venue: E105-108**

**Time: 11:00-12:30**

**Co-Chairs:** Charles Holmes, Georgetown University, United States  
Meg Doherty, World Health Organization, Switzerland

**Impact of the PEPFAR geographic pivot on HIV & non-HIV health services in Uganda**

*J. Wilhelm, L. Paina, M. Qiu, M. Makuru, F. Ssengooba, S. Bennett*  
United States

**From 90-90-90 towards HIV elimination with boosted-integrated active HIV case management (B-IACM) in Cambodia**

*P.S. Ly, V. Ouk, C. Kaoeun, S. Samreth, B. Ngauv, S. Seng, D. Nhim, S. Wignall*  
Cambodia

**Reaching the first "90": Decentralizing and strengthening provider initiated testing services at primary health care facilities in Ukraine**

*M. Makovetska, A. Vasykova, N. Davydenko, O. Yaremenko, N. Avaliani*  
Ukraine

**Monitoring viral load for the last mile: What will it cost?**

*B.E. Nichols, S.J. Girdwood, T. Crompton, L. Stewart-Isherwood, L. Berrie, D. Chimhamhiwa, C. Moyo, J. Kuenhle, S. Rosen, on behalf of EQUIP*  
United States

**The impact of PEPFAR PMTCT funding on reduced infant mortality and improved ANC care in Kenya: A quasi-experimental evaluation**

*D.A. Barnhart, I. Tsikhutsu, F. Sawe, J. Muli, D. Kirui, W. Sugut, N. Abboud, T. Hamm, P. Coakley, P.W. Hickey, V. Wolfman, E. Lee, D. Spiegelman*  
United States

**WEAE03 Money, money, money: Dynamic financing solutions**

Oral Abstract Session

**Venue: G102-103**

**Time: 11:00-12:30**

**Chair:** Anna Vassall, London School of Hygiene and Tropical Medicine, United Kingdom

**Global optimization of the response to HIV**

*J. Stover, Y. Teng*  
United States

**How does domestic HIV/AIDS financing respond to declines in development assistance for HIV/AIDS?**

*A. Haakenstad, M. Moses, T. Tao, A. Chapin, J. Dieleman*  
United States

**Forecasting the cost of financing ART in sub-Saharan Africa under differential funding scenarios**

*T. Frank, A. Carter*  
United States

**Achieving sustainable Workplace HIV/AIDS Programmes through a phased out catalytic financing model: Case of Swedish Workplace HIV/AIDS Programme in sub-Saharan Africa**

*D.M. Mwaura*  
Kenya

**Optimizing resource allocation for HIV prevention programs: Proof of concept of an analytical framework using data from Mexico**

*A. Salas-Ortiz, G. La Hera-Fuentes, S.A. Bautista-Arredondo*  
Mexico

**WEAA01 Poking, prodding and purging the final reservoir frontier**

Oral Abstract Session

**Venue:** G104-105

**Time:** 11:00-12:30

**Co-Chairs:** Damian Purcell, Doherty Institute, Australia  
Ya-Chi Ho, Yale University School of Medicine, United States

**Chidamide reactivates and diminishes latent HIV-1 DNA in patients on suppressive antiretroviral therapy**

Y. Sun, J. Li, J. Ma, C. Wang, F. Bai, K. Zhao, Z. Yu, W. Kang, Y. Zhuang, N. Yao, Q. Liu, B. Dang, B. Wang, Q. Wei, Z. Liu, L. Wang, W. Kang, L. Wang, J. Xia, T. Wang, T. Zhu  
China

**The antiretroviral CCR5-inhibitor maraviroc effectively reverses HIV latency by phosphorylation of Nf- $\kappa$ B**

J. Symons, S.F.L. van Lelyveld, W. de Spiegelaere, A.M.J. Wensing, J.M. Zerbato, P.M. van Ham, J. Drylewicz, A. Middel, A.I.M. Hoepelman, P.U. Cameron, H.K. Lu, A.I. Dantanarayana, J.A.M. Borghans, L. Vandekerckhove, S.R. Lewin, K. Tesselaar, M. Nijhuis  
Australia

**Activation of latent HIV and SIV RNA transcription in vitro and in vivo in ART suppressed SIV-infected rhesus macaques by the Ingenol-based protein kinase C agonist, GSK445A**

A. Okoye, R. Fromentin, J. Brehm, A. Maxwell, M. Vaidya, M. Pardons, V. Tai, J. Tang, J. Smedly, M. Axthelm, J. Lifson, L. Picker, L. Trautmann, D. Favre, N. Chomont  
United States

**The RNA-binding proteins, SRP14 and HMGB3 play a crucial role in controlling HIV replication and latency**

G. Khoury, M.Y. Lee, S. Ramarathinam, S. Sonza, A.W. Purcell, D.F.J. Purcell  
Australia

**Using the PPAR $\gamma$  antagonist to block/lock HIV reactivation in Th17 cells**

Y. Zhang, D. Planas, H. Chen, A. Gosselin, J.-P. Routy, P. Ancuta  
Canada

**The majority of the replication-competent virus in the latent reservoir originates from viruses circulating near the time of ART initiation**

S.B. Joseph, M.-R. Abrahams, N. Garrett, S. Zhou, M. Moeser, W. Burgers, L. Tyers, D. Matten, C. Anthony, O. Council, N. Archin, D.M. Margolis, S. Abdool Karim, R. Swanstrom, C. Williamson  
United States

**WEBS01 Epidemic transition: How will we achieve it while ensuring equity and quality?**

Bridging Session

**Venue:** Forum

**Time:** 11:00-12:30

**Chair:** Mahesh Mahalingam, UNAIDS, Switzerland

The terms "epidemic control" and "epidemic transition" are being used more often as countries work to meet the global commitment to end AIDS as a public health threat by 2030. Stakeholders working on ways to measure control and transition came together in Glion, Switzerland, in October 2017 to put forward a new set of metrics for countries' progress towards the 2030 goal. Achieving this goal means zero new HIV infections, zero discrimination, zero AIDS-related deaths and sustained programmatic support for the millions living with HIV. "Transition" or "control", and the idea of having metrics to measure transition points, raises questions, such as:

How were these metrics established? What do they mean?  
How can they be interpreted?  
What does it mean to reach transition?  
Where are countries now on this path?  
How can we measure how well a response includes human rights?

**Introduction**

M. Mahalingam, UNAIDS, Switzerland

**Keynote address**

D. Birx, The U.S. President's Emergency Plan for AIDS Relief (PEPFAR), United States

**Panel discussion**

C. Beyrer, Johns Hopkins University, United States; J. Amon, Drexel University, United States; U. Munyaburanga, Kigali Hope Association, Rwanda; N. Kilonzo, National AIDS Control Council (NACC), Kenya

**Closing remarks**

M. Mahalingam, UNAIDS, Switzerland

**WESY01 Drugs, drug policy, harm reduction: A reality check**

Symposia Session

**Venue:** Auditorium

**Time:** 11:00-12:30

**Co-Chairs:** Ruth Dreifuss, Former President of Switzerland and Chair Global Commission on Drug Policy, Switzerland  
John-Peter Kools, Trimbos Institute, Netherlands

A reality check in an area where the AIDS response is failing and is meeting with political, structural, and societal challenges. HIV transmission associated with unsafe injecting drug use has increased in the past 6 years; harm reduction has been stagnating globally in terms of reach out and funding; and political resistance to harm reduction is being strongly voiced in many countries. Despite progress in the language of the final resolution of the UN Special Session on drugs of 2016, progress in reforming drug policies towards more humane, public health-driven and human rights-driven policies is slow or lagging. The panel will address the changing landscape of drug use and injecting drug use, the state of harm reduction, and evolving drug policies.

**Welcome and opening remarks**

R. Dreifuss, Former President of Switzerland and Chair Global Commission on Drug Policy, Switzerland; J. Kools, Trimbos Institute, Netherlands

**Drug use worldwide and HIV**

J. Buxton, Central European University, Hungary

**Prohibitionist drug policies, violence and HIV**

D. Joloy, Amnesty International, Mexico

**Harm reduction at a cross roads**

D. Wolfe, Open Society Foundations, United States

**Drug policy as means of social control by governments**

N. Eastwood, Release, United Kingdom

**The perspective of people who use drugs**

J. Chang, International Network of People Who Use Drugs (INPUD), United Kingdom

**Moderated Q&A with panellists and audience**

**IAS Injecting Drug Use Research Prize**

R. Dreifuss, Former President of Switzerland and Chair Global Commission on Drug Policy, Switzerland; M. Klein, McGill University Health Centre, Canada

**Closing remarks**

R. Dreifuss, Former President of Switzerland and Chair Global Commission on Drug Policy, Switzerland; J. Kools, Trimbos Institute, Netherlands

**WESY02 Coming of age with HIV: A testimony of our success and a measure of our readiness for the future**

Symposia Session

**Venue:** Elicium 2

**Time:** 11:00-12:30

**Co-Chairs:** Kate Thomson, The Global Fund to Fight AIDS, Tuberculosis and Malaria, Switzerland  
Annette Sohn, amfAR, the Foundation for AIDS Research, Thailand

This session will explore the issues of 'coming of age with HIV' for adults, children and adolescents. It will show the projections of the growing numbers of people in different ages who have lived with HIV for one or more decades as a measure of the success of the AIDS response. The session will highlight issues that are emerging of ageing with HIV, and also how the subject provides a unique point to examine how well prepared we are to provide uninterrupted and sustainable HIV-specific and generalized (integrated) care beyond 2030 to a growing population of people living with HIV.

## Welcome and introduction

*K.Thomson, The Global Fund to Fight AIDS, Tuberculosis and Malaria, Switzerland; A.Sohn, amfAR, the Foundation for AIDS Research, Thailand*

## Chronic diseases in children and adolescents on antiretroviral therapy: preparing for what is to come

*T.Puthanakit, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand, Thailand*

## Living with HIV, on treatment for life, and growing older: the impact on the body and mind

*L.Mendao, Coalition Plus, EATG, GAT, Portugal*

## Caring for Older People with HIV: Challenges and Best Practices

*E.Siegler, Weill Cornell University, United States*

## Panel discussion: A testimony of our success and a measure of our readiness for the future

*L.Maturu, Africaid Zvandiri, Zimbabwe; S.Widen, Pharmaccess, Netherlands; T.Puthanakit, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand, Thailand; L.Mendao, Coalition Plus, EATG, GAT, Portugal; E.Siegler, Weill Cornell University, United States*

## Q&A

### Regional Members' Meeting for Africa

Regional Session

**Venue:** Emerald Room

**Time:** 11:00-12:00

**Co-Chairs:** Alex Muganga Muganzi, Regional Representative on the IAS Executive Committee, Serge Eholie, University Teaching Hospital, Abidjan, Cote D'Ivoire, James Hakim, University of Zimbabwe, Kenneth Ngure, University of Washington, Kenya, Keletso Makofane, Harvard University, United States

## Introduction: a year in the IAS (summary of programmes and activities developed over the past year and membership numbers)

### IAS Educational Fund meeting in Abijan, Côte d'Ivoire

#### Membership engagement

## WEWS01 Challenging criminalization globally: Un-policing identity, morality, sexuality and bodily autonomy

Leadership Workshop

**Venue:** E102

**Time:** 11:00-12:30

**Level:** Intermediate

**Target audience:** Activist, Advocate, Lawyer

**Seating limit:** 240

**Co-Facilitators:** Bob Mwiinga Munyati, AIDS Accountability International, South Africa, Phillipa Deidre Tucker, AIDS Accountability International, Belgium

Across the globe, courts, parliaments and law enforcement agencies are increasingly using the coercive power of the law to police, control and punish a variety of behaviours which they considered as contributing to 'moral decay'. The activities, identities, and states of being that come under this rubric include consensual sexual relations between persons of the opposite sex, sodomy, abortion, sex work, adultery, pornography, drug use, being a person of colour, and being a sex worker among others. This workshop will rethink how and who should be working with the community to limit the impact of penal provisions on the achievement of the end of the AIDS epidemic and the achievement of the SDGs.

## Facilitator and introduction to the CCG Project and the April Rethink Meeting outcomes

*B.Munyati, AIDS Accountability International, South Africa*

## Civil society perspective on need to limit punitive justice

*S.Fried, Yale University, United States*

## Contributions of the Global Commission on HIV and the law to addressing criminalization

*K.Esom, United Nations Development Programme (UNDP), Switzerland*

## TBC

*S.Ndashe, ISLA, Netherlands*

## Chase the virus, not people

*N.Podogova, Eurasian Harm Reduction Association (EHRA), Lithuania*

## TBC

*E.Bernard, HIV Justice Network, United Kingdom*

## TBC

*R.Nathanson, KPEG, Zimbabwe*

## Questions and answers

*B.Munyati, AIDS Accountability International, South Africa*

## WEWS02 The intersection of mental disorder screening and treatment and HIV/AIDS in LMICs: State of the science and priority directions

Public Workshop

**Venue:** GV Session Room 1

**Time:** 11:00-12:30

The purpose of this workshop is to provide an overview of state-of-the-science approaches for screening and intervention for mental disorders among persons living with HIV in low and middle-income settings. The audience will learn about (a) research that is being conducted to address depression in HIV care, (b) screening and addressing trauma among women in HIV care, (c) adaptation of evidence-based mental health interventions for delivery in low resource settings, and (d) interventions to improve mental health and HIV care outcomes among children and youth living with HIV.

## Task-shifting treatment for depression and non-adherence to antiretroviral therapy

*M.Abas, Centre for Global Mental Health, United Kingdom*

## Using task shifting approaches to treat depression in HIV primary care settings: Lessons learned along the way

*C.O'Cleirigh, Harvard University Center for AIDS Research, United States*

## Leveraging success in HIV for scale up of evidence-based mental health care in East Africa

*K.Sikkema, Duke University, United States*

## Integrating trauma treatment to enhance HIV care engagement in low resource settings

*S.Meffert, UCSF Medical Centre, United States*

## Promoting mental health in adolescents growing up with HIV

*C.Mellins, Columbia University, United States*

## Moderated discussion interaction with the audience

*C.Gordon, National Institute of Mental Health (NIMH), United States*

**WEWS03 Trans identities: Importance of recognition in the law and research to address HIV and health disparities**

Public Workshop

**Venue:** GV Session Room 2

**Time:** 11:00-12:30

The session will explore the relationship between HIV and structural barriers that face trans health, primarily legal recognition and the lack of disaggregated data recognizing trans identities. Researchers, activists, and policymakers from throughout the Asia and Pacific region will share what this inclusion looks like and the effect that recognition of trans people has in data-driven research, policy, and health.

**Welcome and introduction**

*P. Brown-Acton, INA (Maori, Indigenous & South Pacific) HIV/AIDS Foundation, New Zealand*

**Health mapping and LGR**

*P. Brown-Acton, INA (Maori, Indigenous & South Pacific) HIV/AIDS Foundation, New Zealand*

**Breakout sessions**

**Research and data disaggregation**

*A. Arcon, Pioneer Filipino Transgender Men Movement, Philippines*

**Pakistan Trans Rights Bill areas of collaboration**

*A. Mughal, Pakistan's National Commission on Human Rights, Pakistan*

**Health dialogue and policy: Tonga blueprint workshop**

*C. Kingnukuturn, Tonga Leitis Association, Tonga*

**Health provision: TRCARC**

*R. Janamnuaysook, Thai Red Cross AIDS Research Centre, Thailand*

**Breakout groups and action plans**

**Reporting back from group work**

**Closing remarks**

*P. Brown-Acton, INA (Maori, Indigenous & South Pacific) HIV/AIDS Foundation, New Zealand*

**WEPDC01 From online to IRL: Social media, sex apps and surfing to enhance cascades**

Oral Poster Discussion Session

**Venue:** Hall 11A

**Time:** 13:00-14:00

**Co-Chairs:** Alex Garner, Hornet, United States  
Midnight Poonkasetwattana, Asia Pacific Coalition on Male Sexual Health (APCOM), Thailand

**Implementation and impact of a technology-based HIV risk-reduction intervention among Thai men who have sex with men using 'Vialogues': A randomized controlled trial**

*T. Anand, C. Nitpolprasert, J. Jantarapakde, R. Meksen, S. Phomthong, P. Phoseeta, P. Phanuphak, N. Phanuphak Thailand*

**P3 (Prepared, Protected, emPOWERed): Feasibility and acceptability of a PrEP adherence app featuring peer-to-peer sharing, game-based elements and in-app adherence counseling**

*S. Legrand, K. Knudtson, K. Muessig, M. Dixon, A. Mcgee, J. Dormitzer, R. Jackson, E. Adam, L. Hightow-Weidman United States*

**Effectiveness of community-led sex-positive campaign on HIV testing for young men who have sex with men (YMSM) in Metro Manila (MM), Philippines: TestMNL**

*L.-A.F.M. Lomarda, R.G. Pagtakhan, P.J. Tanpoco Philippines*

**Internet-based self-testing model - "Easy Test": A cross-sectional survey targeting MSM who never tested before in 14 provinces of China**

*X. Jin, D. Xiao, X. Xiu, Z. Ding, Y. Zhang, Y. Jie, Y. Liao, H. Wu, N. Cao, B. Shepherd, J. Vandenhomborgh, Y. Bao China*

**From online reach to offline services: Using social media strategies to increase uptake of and access to HIV testing among MSM in Vietnam**

*T.T. Tran, K. Green, V.D. Nguyen, N.B. Vu, T.T. Nguyen, T.T. Doan, M.T. Le, M.T. Ngo Vietnam*

**Online supervised HIV self-testing identified high HIV yield among Thai men who have sex with men and transgender women**

*J. Jantarapakde, K. Himmad, T. Sungsing, S. Promthong, W. Waiwinya, P. Meekrua, S. Sukthongsa, S. Hongwiangchan, N. Upanun, D. Trachunthong, S. Barisi, S. Jirajariyavej, S. Charoenying, S. Mills, R. Vannakit, M. Cowing, S. Buchbinder, N. Phanuphak Thailand*

**WEPDA01 All fired up: Tackling inflammation**

Oral Poster Discussion Session

**Venue:** Hall 11B

**Time:** 13:00-14:00

**Chair:** Lishomwa Ndhlovu, University of Hawaii&#699;i at Manoa, United States

**Antiretroviral treatment did not restore functionality of cervical mucosal cells for Th17-related cytokines altered after HIV infection**

*M.P. Caruso, M.P. Holgado, J. Falivene, J. Salido, D.H. Zurita, A. Nico, V. Fink, N. Laufer, H.M. Perez, P. Cahn, O. Sued, G. Turk, M.M. Gherardi Argentina*

**Effect of ART on reducing fungal translocation in HIV-infected patients**

*J.P. Routy, V. Mehraj, R. Ramendra, C. Costiniuk, B. Lebouché, J. Chen, R. Ponte, R. Thomas, B. Trottier, J. Szabo, P. Coté, R. LeBlanc, J.-G. Baril, N. Bernard, D. Sheppard, C. Chartrand-Lefebvre, M. El-Far, M. Durand, H. Lu, C. Tremblay, Montreal Primary HIV-infection Study and Canadian HIV and Aging Cohort Study Groups Canada*

**Persistence of myeloid cell-associated inflammation in HIV-infected children after 8 years on early initiated therapy - the key role players in HIV persistence?**

*S. Naidoo, K. Veldsman, M.F. Cotton, R.H. Glashoff South Africa*

**Immune activation parameters are differentially expressed across four countries in sub-Saharan Africa and are associated with comorbidities in HIV + and HIV- individuals**

*H. Streeck, G. Son, D. Habermann, T.A. Crowell, A. Esber, L.A. Eller, M.A. Eller, A.P. Parikh, P.A. Horn, L. Maganga, Y. Adamu, F. Kiweewa, J. Maswai, J. Owuoth, M.L. Robb, N.L. Michael, D. Hoffmann, C.S. Polyak, J.A. Ake Germany*

**Anticoagulant therapies alleviate SIV-associated hypercoagulation as well as immune activation and inflammation**

*T. He, G. Haret-Richter, B. Andrade, C. Xu, B. Policicchio, P. Sette, K. Raehz, E. Falwell, T. Dunsmore, K. Martin, G. Padovani, I. Francischetti, C. Apetrei, I. Sereti, I. Pandrea United States*

**WEPDD01 Occupy the epidemic: Economic inequality and HIV**

Oral Poster Discussion Session

**Venue:** E105-108

**Time:** 13:00-14:00

**Co-Chairs:** Jamila Headley, Health GAP, United States  
Allan Maleche, KELIN, Kenya

**Examining the socioeconomic gradient in viral suppression in Malawi**

*L. Sithole, A. Palma, D. Payne, E. Kim, C. West, M. Nzima, G. Bello, MPHIA Study Team Malawi*

**Food insecurity is common and associated with unsuppressed viral load in HIV-infected pregnant women in Kenya**

*K. Ronen, L. Osborn, B. Khasimwa, B. Chohan, D. Matemo, J. Unger, A. Drake, J. Kinuthia, G. John-Stewart United States*

**The impact of homelessness in achieving viral suppression among extremely low-income HIV-infected women living in a well-resourced US city: A longitudinal perspective of overlapping risks**

*E.D. Riley, E. Vittinghoff, K.A. Christopoulos, A. Clemezi-Allen, S.E. Dilworth-Johnson, C.A. Koss, A.W. Carrico*  
United States

**Unstable housing associated with injection risk behaviors among PWID in Ukraine**

*A. Mazhnaya, J. Owczarzak*  
United States

**Displacement, urban gentrification and declining access to HIV/STI, sexual health and outreach services amongst women sex workers between 2010-2014: Results of a community-based longitudinal cohort**

*S. Goldenberg, O. Amram, M. Braschel, S. Machat, K. Shannon, on behalf of the AESHA Study Team*  
Canada

**WEPDC02 Sex and drugs: Ongoing syndemics in the PrEP and treatment era**

Oral Poster Discussion Session

**Venue:** G102-103

**Time:** 13:00-14:00

**Co-Chairs:** Heather-Marie Schmidt, Asia Pacific Coalition for Men's Sexual Health (APCOM), Australia  
Peter O. Preko, ICAP at Columbia University, Swaziland

**Syndemics predict bio-behavioral HIV sexual transmission risk (TRB) longitudinally in US HIV clinics**

*S. Satyanarayana, S.A. Safren, B.G. Rogers, S.A. Bainter, K.A. Christopoulos, R.J. Frederickson, W.C. Mathews, R.D. Moore, M.J. Mugavero, S. Napravnik, M.J. Mimiaga, K.H. Mayer, H.M. Crane*  
United States

**Correlates of benzodiazepine and opioid co-prescription among people living with HIV in British Columbia, Canada**

*S. Parent, S. Nolan, N. Fairbairn, M. Ye, A. Wu, J. Montaner, R. Barrios, L. Ti, STOP HIV/AIDS Study Group*  
Canada

**When sex, drugs and violence overlap: Assessing the syndemic and synergistic effects of intimate partner violence, crystal methamphetamine, and depression on HIV sexual risk among women who inject drugs**

*C. Stoicescu, L.D. Cluver, R. Ameilia*  
United Kingdom

**Combination prevention for women who use alcohol in South Africa: Outcomes from the Women's Health CoOp Plus Study in Pretoria, South Africa**

*W. Wechsberg, W. Zule, C. van der Horst, C. Peasant Bonner, J. Ndirangu, F. Browne, T. Kline, B. Howard, N. Rodman*  
United States

**Behavioral activation integrated with sexual risk reduction counseling for high-risk MSM with crystal methamphetamine dependence: An initial randomized controlled trial**

*M. Mimiaga, D. Pantalone, K. Biello, J. White Hughto, J. Frank, C. O'Cleirigh, S. Reisner, A. Restar, C. Santostefano, K. Mayer, S. Safren*  
United States

**Association between syndemics (of alcohol and drug use, and violence) and HIV-related sexual risk among men who have sex with men in India: Findings from a large-scale national bio-behavioural survey**

*V. Chakrapani, P.V.M. Lakshmi, P. Kumar, V. Srinivas*  
India

**WEPDE01 Keeping it up: National ownership and financial sustainability**

Oral Poster Discussion Session

**Venue:** G104-105

**Time:** 13:00-14:00

**Co-Chairs:** Sergio Bautista, National Institute of Public Health (INSP), Mexico  
Shufang Zhang, The Global Fund to fight Aids, Tuberculosis and Malaria, Switzerland

**Lessons learned from sustained global health investments**

*A. Downer, J. Johnstone, M. McDowell, E.M. Reyes*  
United States

**How it was possible to offer Integrase Inhibitor as first line ART while maintaining the sustainability of the Brazilian policy of universal access to drugs**

*C.J.B. Batista, R.G. Corrêa, E. Malheiros, M.D.A. Freitas, A.S. Benzaken*  
Brazil

**Cost of HIV care and treatment in Mozambique**

*A. Berruti, A. Krivlyova, F. Mbofana, D. Single, A. Vergara*  
United States

**Building sustainable HIV service delivery model at a local level in Ukraine**

*O. Iaromenko, A. Vasykova, L. Khomych, N. Avaliani, N. Davydenko, M. Makovetska*  
Ukraine

**Sustainable financing of the HIV response in Vietnam: Integration of donor funded treatment facilities into public health system and the social health insurance scheme**

*H.T. Nguyen, H.T. Nguyen, A.T.C. Nguyen, H. Pham, A.N. Le, L. Dam, D. Nguyen, N. Todini, N.T. Do, H.T.T. Phan, T.M. Hammett*  
Vietnam

**PEPFAR's Sustainability Index and Dashboard: Results from SID 3.0**

*C. Hart, M. Ruffner, J. Timberlake, M. Wollmers*  
United States

**WEPDB01 Acute infection and viral reservoir**

Oral Poster Discussion Session

**Venue:** E102

**Time:** 13:00-14:00

**Co-Chairs:** Brad Jones, Weill Cornell Medicine and The George Washington University, United States  
Godelieve de Bree, Amsterdam Institute for Global Health and Development, Netherlands

**Validation of Alere TM q HIV-1/2 detect for detection of acute HIV infection at Anonymous Clinic, The Thai Red Cross AIDS Research Centre**

*I. Srila-Oi, T. Pankam, S. Pattanachaiwit, S. Barisri, P. Raprasert, J. Jantarapakde, S. Areeyowattana, S. Sirivichayakul, P. Phiyaura, R. Ramautarsing, N. Phanuphak, P. Phanuphak*  
Thailand

**Favorable clinical phenotype reached in less than half of people treated in acute HIV infection**

*I. Ananworanich, S. Pinyakorn, A. Avihingsanon, J. Sophonphan, C. Sacdalan, E. Kroon, D. Colby, D. Suttichom, P. Prueksakaew, S. Uboiyam, R. Trichavaroj, M. de Souza, N. Michael, M.L. Robb, P. Phanuphak, N. Phanuphak, on behalf of the RV254/SEARCH 010 and HIV-NAT 006 Study Groups*  
United States

**Increasing contribution of integrated forms to total HIV1-DNA in blood, in primary infection during natural history - ANRS PRIMO and SEROCO cohorts**

*P. Tremeaux, T. Lenfant, F. Boufassa, A. Essat, A. Melard, M. Gousset, O. Delelis, J.-P. Viard, M. Bary, C. Goujard, C. Rouzioux, L. Meyer, V. Avettand-Fenoel, SEROCO and PRIMO ANRS Cohorts*  
France

**Intermittent viremia after treatment interruption increased risk of ART resumption in post-treatment HIV-1 controllers. ANRS VISCONTI study**

*L. Hocqueloux, V. Monceaux, V. Avettand-Fenoël, S. Orr, F. Boufassa, O. Lambotte, T. Prazuck, P. Mialhes, D. Salmon, C. Lascoux-Combes, A. Lafeuillade, L. Meyer, M. Müller-Trutwin, C. Rouzioux, A. Saez-Cirion, ANRS VISCONTI Study*  
France

**Auranofin plus nicotinamide impact HIV reservoir among ART suppressed HIV individuals**

*L.B. Giron, J. Hunter, J. Galinskas, D. Dias, P.R.A. Ferreira, S. Tenore, G. Gosuen, S. Samer, M.S. Arif, E.D. Libera, A. Savarino, L.M.R. Janini, M.C.A. Sucupira, R.S. Diaz*  
Brazil

**WEPDB02 Antiretrovirals: Pharmacokinetics and generics**

Oral Poster Discussion Session

**Venue:** Emerald Room

**Time:** 13:00-14:00

**Chair:** Marta Boffito, Chelsea and Westminster Hospital, United Kingdom

**Co-Chairs:** Adeodata Kekitiinwa, Baylor College of Medicine Children's Foundation, Uganda  
Denis Tindyebwa, ANECCA, Uganda

**TB/HIV co-treatment with super-boosted lopinavir and anti-tuberculosis treatment lowers abacavir concentration in children**

H. Rabie, T. Tikiso, H. McIleron, J. Lee, I. Andrieux-Meyer, M. Cotton, M. Lallemand, P. Denti  
South Africa

**Efavirenz plasma exposure and immunologic outcome during anti-tuberculosis co-therapy: Role of ethnicity and pharmacogenetic variations**

S. Mugusi, W. Amogne, A. Habtewold, E. Ngaimisi, G. Yimer, O. Minzi, E. Makonnen, F. Mugusi, C. Sudfeld, M. Janabi, J. Burhenne, E. Akillu  
Tanzania, United Republic of

**A randomized, open-label, balanced, two-treatment, single-dose, crossover oral bioequivalence study of Lopinavir/Ritonavir Granules 40mg/10mg with KALETRA® (Lopinavir/Ritonavir) Oral Solution 80 mg/20mg per mL in normal healthy adults under fed conditions**

D. Abhijit, C. Santanu, D. Akhilesh, K. Umakant, R. Bangaru, A.K. Datla, P. Deshpande, A. Kanda, E. Patras, S. Gahoj  
India

**Single-dose fed bioequivalence study of Lamivudine, Tenofovir Disoproxil Fumarate and Dolutegravir tablets (300mg/300mg/50mg) versus EPIVIR® tablets (300mg; ViiV-Healthcare), VIREAD® tablets (300mg; Gilead Sciences) and TIVICAY® tablets (50mg; ViiV-Healthcare) in healthy adult volunteers**

D. Abhijit, C. Santanu, R. Chetan, S. Gahoj, R. Bangaru, A.K. Datla, P. Deshpande, A. Kanda, E. Patras  
India

**Population pharmacokinetics of cabotegravir in adult healthy subjects and HIV-1 infected patients following administration of oral tablet and long acting intramuscular injection**

K. Han, P. Patel, M. Baker, D. Margolis, W. Spreen, S. Ford  
United States

**WEES01 Durable control of HIV infections in the absence of antiretroviral therapy: Opportunities and obstacles and Jonathan Mann Memorial Lecture: Data to drive equity**

Special Session

**Venue:** Hall 12

**Time:** 13:00-14:00

**Co-Chairs:** Pedro Cahn, Fundacion Huesped, Argentina  
Lambert Grijns, Ministry of Foreign Affairs, Netherlands

In the first part of this special session, Dr Anthony Fauci will address why induction of durable remission of HIV infection remains a critical challenge in HIV/AIDS research. Two key paths toward remission are being pursued: 1) use of intermittent, non-ART interventions, and 2) induction of durable, immune-mediated control of virus. The speaker will review progress in each area and the obstacles that lie ahead as researchers pursue this essential goal.

The second part of the session will feature Ambassador Deborah Birx, recipient of the prestigious Jonathan Mann Human Rights Award, delivering the associated lecture.

**Welcome and introduction**

**Durable control of HIV infection in the absence of antiretroviral therapy: Opportunities and obstacles**  
A. Fauci, National Institutes of Health (NIH), United States

**Jonathan Mann Memorial Lecture: Data to drive equity**

D. Birx, The U.S. President's Emergency Plan for AIDS Relief (PEPFAR), United States

**WEAB02 ART in infants and children**

Oral Abstract Session

**Venue:** Hall 10

**Time:** 14:30-16:00

**Developmental and cognitive effects of type of antepartum and postpartum ARV exposure for Ugandan and Malawian IMPAACT PROMISE HIV-exposed versus unexposed children at age 12, 24 and 48 months**

M. Boivin, L. Maliwichi-Senganimalunje, L. Wambuzi Ogwang, R. Kawalazira, A. Sikorskii, I. Familjar-Lopez, A. Kuteesa, M. Nyakato, A. Mutebe, M. Makitende, M. Mallewa, H. Ruisenor-Escudero, J. Aizire, T. Taha, M.G. Fowler  
United States

**Central nervous system toxicity of efavirenz in HIV-infected children in Tanzania**

L. Van de Wijer, D.N. Mchale, A.F.A. Schellekens, N.N.J. Lambregts-Rommelse, Q. de Mast, B.T. Mmbaga, A.J.A.M. van der Ven, G.D. Kinabo  
Netherlands

**Outcomes of second-line antiretroviral therapy (ART) in HIV-infected children: A CIPHER cohort collaboration global analysis**

K. Patel, C. Smith, I.J. Collins, R. Goodall, E. Abrams, A. Sohn, T. Mohamed, R. Van Dyke, P. Rojo, K. Wools-Kaloustian, J. Pinto, A. Edmonds, I. Marete, M. Paul, H. Nuwaqaba-Biribonwoha, V. Leroy, M.-A. Davies, R. Vreeman, Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Cohort Collaboration  
Duration of Second-line Proj  
United States

**Pellets' formulation of Lopinavir/ritonavir in children: 48-week evolution of viral suppression across age categories in the LIVING study**

I. Andrieux-Meyer, O. Salami, R. Omollo, T. Egondi, M. Waweru, S. Odiambo, M. Wasunna, V. Musiime, E. Obimbo, E. Bukusi, P. Oyar, J. Mwanga-Amumpaire, J. Mbuthia, J. Lee, F. Kyhomuhendo, F. Simon, W. Nyandiko, A. Kekitiinwa, M. Lallemand, D. Wamalwa, LIVING Study Group  
Kenya

**Pharmacokinetics, safety, and efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) single-tablet regimen in HIV-1-infected children (6 to < 12 years)**

M. Cotton, A. Liberty, C.A. Rodriguez, K. Chokephaibulkit, P. Kosalaraksa, E. Hellstrom, E. Natukunda, P. Wong, S.R. Majeed, E. Quirk, H. Graham, C. Pikora  
South Africa

**Impact of late versus early antiretroviral therapy on BMC-associated HIV-1-DNA levels and the percentage of naive T lymphocytes in HIV-1 infected children and adolescents - The ANRS-EP59-CLEAC study**

P. Frange, V. Avettand-Fenoel, J. Le Chenadec, C. Dollfus, L. Nailler, O. Dialla, T. Montange, D. Batalie, M. Fillion, I. Leymarie, L. Ait Si Selmi, T. Wack, J. Warszawski, F. Buseyne, ANRS-EP59-CLEAC Study Group  
France

**WEAE04 PrEP: Work in progress**

Oral Abstract Session

**Venue:** Elicium 1

**Time:** 14:30-16:00

**Chair:** Nyaradzo Mavis Mgodli, University of Zimbabwe, Zimbabwe

**Factors influencing initiation, continuation & discontinuation of oral PrEP at selected facilities in South Africa**

D. Pillay, S. Jenkins, M. Murire, K. Stankevitz, H. Subedar, S. Mullick  
South Africa

**PrEP uptake among pregnant and postpartum women: Results from a large implementation program within routine maternal child health (MCH) clinics in Kenya**

J. Kinuthia, J. Pintye, F. Abuna, H. Lagat, K. Mugwanya, J. Dettinger, M. Serede, J. Sila, J.M. Baeten, G. John-Stewart, PrEP Implementation for Young Women and Adolescents (PrIYA) Program  
Kenya

**How long will they take it? Oral pre-exposure prophylaxis (PrEP) retention for female sex workers, men who have sex with men and young women in a demonstration project in Kenya**

J.K. Kyongo, M. Kiragu, R. Karuga, C. Ochieng, A. Ngunjiri, C. Wachihi, H. Musyoki, L. Digolo, L. Otiso, L. Gelmon, N. Kilonzo, W. Mukoma  
Kenya

## Cost and impact of PrEP implementation in Haiti to adopt WHO recommendations: Results from EQUIP

R. Kolesar, K. Rebe, D. Lauture, [S.N. Magwaza](#), W.J. Domercant, E. Emmanuel, M. Leonard, M.-L. Excellent, F.J. Louis, EQUIP PrEP Technical Working Group  
South Africa

## The cost-effectiveness of multi-purpose HIV and pregnancy prevention technologies in South Africa

[M. Quaipe](#), F. Terris-Prestholt, R. Eakle, M. A Cabrera Escobar, M. Kilbourne-Brook, M. Mvundura, G. Meyer-Rath, S. Delany-Moretlwe, P. Vickerman  
United Kingdom

## Incidence of HIV-infection in the ANRS Prevenir study in Paris region with daily or on-demand PrEP with TDF/FTC

[J.-M. Molina](#), J. Ghosn, L. Béniguel, D. Rojas-Castro, M. Algarte-Genin, G. Pialoux, C. Delaugerre, Y. Yazdanpanah, C. Katlama, C. Séguin, S. Morel, C. Pintado, B. Loze, S. Le Mestre, S. Gibowski, V. Doré, L. Assoumou, B. Spire, D. Costagliola, Prevenir ANRS study group  
France

## WEAD02 Time for a youthquake in HIV prevention and treatment

Oral Abstract Session

**Venue:** Hall 11A

**Time:** 14:30-16:00

**Co-Chairs:** Nadia Adjoa Sam-Agudu, Institute of Human Virology Nigeria, Nigeria  
Kelvin Makura, Zimbabwe Young Positives, Zimbabwe

## The association between incarceration and transactional sex among HIV-positive young men who have sex with men (YMSM) in the United States

[M. Philbin](#), E. Kinnard, A. Tanner, S. Ware, B. Chambers, A. Ma, J.D. Fortenberry  
United States

## Gendered powerlessness in at-risk adolescent and young adult women: An examination of condom use behavior

[D. Chharamonte](#), R.L. Miller, C.B. Boyer, K.S. Lee, O.J. Santiago-Rivera, Adolescent Medicine Trials Network for HIV/AIDS Interventions  
United States

## Ethnographic study for HIV prevention reveals a typology consisting of five distinct types among South African adolescents and young women

K. Crowley, J. Piper, J. Cummins, G. Gao Guodong, L. Burn, K. Igumbor, [R. Agarwal](#), F. Veronese  
United States

## Should I take PrEP? A mental models assessment of young African women's motivations for and barriers to PrEP initiation and adherence

[N. Argo](#), T. Krishnamurti, B. Fischhoff, L.-G. Bekker, S. Delany-Moretlwe, E. Bukusi, L. Myers, J. Imrie, J. Odoyo  
United States

## Experiences and outcomes of group psychotherapy as an antiretroviral adherence support intervention among young people failing on ART at Newlands Clinic, Harare, Zimbabwe

[B.M. Kasimonje](#), T. Shamu, C. Chimbetete  
Zimbabwe

## The third generation of HIV: World first longitudinal study of pregnancy in adolescents living with HIV

[E. Toska](#), L. Sherr, L. Cluver, S. Zhou, Mzantsi Wakho Cohort Study  
South Africa

## WEAA02 Killers or helpers: The double life of T cells

Oral Abstract Session

**Venue:** Hall 11B

**Time:** 14:30-16:00

**Co-Chairs:** Lisa Chakrabarti, Institut Pasteur, France  
Julia Prado, IrsiCaixa Institute for AIDS Research, Spain

## Increase in restriction factor expression in response to viral rebound after analytical treatment interruption in HIV-infected patients

[M.-A. De Scheerder](#), C. Van Hecke, N. De Langhe, M. Sips, L. Vandekerckhove

Belgium

## RhCMV-induced, SIV-specific MHC-E-restricted T cells recognize SIV through the T cell receptor

[S. Abdulhaqq](#), B. Bimber, H. Wu, A. Ventura, K. Wisskirchen, A. Legasse, M. Axthelm, U. Protzer, S. Hansen, D. Douek, L. Picker, J. Sacha

United States

## Genetic factors leading to loss of viral control in HIV elite controller patients

[J.M. Benito](#), M. García, V. de Santisteban, R. Ramos, C. Restrepo, M.A. Navarrete-Muñoz, A. León, E. Ruiz-Mateos, A. Cabello, J. Alcamí, M. Górgolas, N. Rallón, On behalf of ECRIS integrated in the Spanish AIDS Research Network  
Spain

## Frequent generation of HIV broadly neutralizing antibodies in infected children is associated with both increased help and regulation within germinal centers

[J. Roeder](#), T. Maehara, A. Ngoepe, D. Ramsuran, M. Muenchhoff, E. Adland, T. Aicher, S. Kazer, P. Jooste, F. Karim, W. Kuhn, A. Shalek, T. Ndung'u, L. Morris, P. Moore, S. Pillai, P. Goulder, H. Kloverpris, A. Leslie  
South Africa

## Initiation of antiretroviral therapy during hyperacute HIV infection preserves germinal center T follicular (GCTfh) helper cell function

[O. Baiyegunhi](#), F. Laher, K. Dong, B. Walker, T. Ndungu, [Z. Ndhlovu](#)  
South Africa

## WESY03 Civil society under threat: How can HIV advocates resist the impact? Conservative populism and social exclusion of civil society

Symposia Session

**Venue:** Hall 12

**Time:** 14:30-16:00

**Co-Chairs:** Jonathan Cohen, Open Society Foundations, United States  
Karyn Kaplan, Asia Catalyst, United States

Repression of civil society is rising. In 2012-2015, more than 120 laws restricting civil rights were introduced or proposed in 60 countries. Governments are implementing legal, administrative and other measures restricting operations of non-governmental organizations, particularly those rooted in marginalized communities disproportionately affected by HIV. Repression tools include burdensome registration requirements, restrictions on basic freedoms (including peaceful assembly and online expression), physical attacks and imprisonment.

Panellists will explore the impacts of civil society restrictions and human rights violations on the HIV response and they will discuss how HIV advocates can defend essential civil liberties.

### Introduction

[J.Cohen](#), Open Society Foundations, United States; [K.Kaplan](#), Asia Catalyst, United States

### Short film that illustrates impact on civil society organizations and rights advocates

[P.Sárosi](#), Rights Reporter Foundation, Hungary

### Experiences from the ground: Russia

[I.Varentsov](#), Eurasian Harm Reduction Association, Lithuania

### Experiences from the ground: Venezuela

[A.Nieves Alberti](#), Acción Ciudadana Contra el SIDA (ACCSI), Venezuela

### Experiences from the ground: Philippines

[J.Bagas](#), APCASO, Thailand

### Experiences from the ground: Kenya

[T.Saoyo](#), Kelin, Kenya

### Moderated discussion

[S.Mellors](#), International HIV/AIDS Alliance, United Kingdom

### Q&A and Final remarks

[S.Mellors](#), International HIV/AIDS Alliance, United Kingdom; [J.Cohen](#), Open Society Foundations, United States

## WESY04 Coinfections: Old and new

Symposia Session



**Venue:** Auditorium  
**Time:** 14:30-16:00

**Co-Chairs:** Cristiana Oprea, Carol Davila University of Medicine and Pharmacy, Romania  
Annabel Baddeley, World Health Organization (WHO), Switzerland

This session will discuss the latest data on the epidemiology, pathophysiology, treatment and prevention of tuberculosis, viral hepatitis from A to E, the emerging threats in infectious diseases, and their interplay with HIV. New tools for screening tuberculosis will be explored, whereby experts will browse and update the therapeutic landscape with a special focus on the issue of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis. It will also discuss the lengthy road to hepatitis C elimination, the new strategies developed to possibly eradicate hepatitis B, and how the epidemics of hepatitis A and E may be controlled in special populations. Finally, specific talks will address the old and new threats in infectious diseases in the context of HIV (haemorrhagic fevers, invasive fungal infections, etc.).

## Introduction

### Re-emerging hepatitis A

*P.Yi-Chun Lo, Taiwan CDC,*

### TB shorter courses and new drugs

*R.Chaisson, Johns Hopkins University, United States*

### Elimination of hepatitis B

*K.Lacombe, Saint-Antoine Hospital (AP-HP), France*

## Panel discussion

## Closing remarks

### WESY05 Key population-led health services: Optimizing prevention and care

Symposia Session

**Venue:** Elicium 2

**Time:** 14:30-16:00

**Co-Chairs:** Nittaya Phanuphak, Thai Red Cross AIDS Research Centre, Thailand  
Kimberly Green, PATH, Vietnam

This session will be aimed at creating awareness of the need, feasibility, effectiveness, and sustainability of the Key Population Community-Led Health Services (KP-CLHS) model in enhancing both the prevention and care cascades. The KP-CLHS model defines a set of HIV-related health services delivered by KP-run community-based organizations in partnership with health sector entities. In this context, KP community leadership means that the KP community itself identifies the services necessary for addressing the HIV epidemic and related health issues; services are therefore needs based, demand driven, and client centred.

## Introduction and setting the stage on the need for KPLHS

### KP clients: Our needs matter when getting us into services (people who inject drugs – PWID)

*S.Moroz, Eurasian Women's Network on AIDS, Georgia*

### KP clients: Our needs matter when getting us into services (transgender woman – TGW)

*A.Kröger, Ministry of Health, Brazil*

### Working with health care professionals and addressing structural barriers to improve key populations access to quality health care services

*M.Hellard, Burnet Institute, Australia*

### KP community health workers: What can KP community health workers offer

*P.Chanleunr, Mplus Foundation, Thailand*

### PLHIV-led health services: holistic and traditional approach for HIV care

*P.Simonsen, SAMI+, Norway*

### Policy maker: supporting policy makers to advance the legalization and direct financing of KP-CLHS

*H.Thi Phan, Ministry of Health, Vietnam, Vietnam*

## Questions and answers from audiences

## Take-home messages from each panellist

## Wrap-up message from the co-chairs

### WESY06 New policies and contexts that negatively impact on funding for the response to HIV

Symposia Session

**Venue:** Forum

**Time:** 14:30-16:00

**Chair:** Peter Piot, London School of Hygiene & Tropical Medicine (LSHTM), United Kingdom

This session will examine how new contexts (such as the migration crisis in Western Europe and change in administration in the US) or new policies negatively impact on funding for HIV/AIDS in general or funding for specific areas relevant to the AIDS response. The session will discuss why and how the priority for AIDS may not be able to remain in the face of these new restrictive contexts and policies.

## Welcome and introduction

*P.Piot, London School of Hygiene & Tropical Medicine (LSHTM), United Kingdom*

## Navigating the current political landscape and it's challenges

*P.Gaspard, Open Society Foundations, United States*

## Are we regressing on global public goods, multilateralism, social justice in times of nationalism and populism?

*M.Dhaliwal, United Nations Development Programme (UNDP), United States*

## The fragile progress on gender equality and access to sexual reproductive health (SRH) for women

*Y.Pillay, National Department of Health, South Africa*

## Ability to pay does not always translate to funding for civil society

*A.Volgina, Global Network of People Living with HIV (GNP+), Netherlands*

## Moderated Q&A

## Conclusion

*P.Piot, London School of Hygiene & Tropical Medicine (LSHTM), United Kingdom*

### WEWS07 Cost-effectiveness - What is it and does it matter?: Understanding and applying cost-effectiveness for high impact HIV testing programmes in low- and middle-income countries

Science Workshop

**Venue:** E102

**Time:** 14:30-17:00

**Level:** Foundation

**Target audience:** Manager / Director, Implementation science researcher, Public sector

**Seating limit:** 240

Through this scientific workshop, participants will understand findings and implications of cost-effectiveness and impact models; and leave with comprehension of costing, cost-effectiveness, impact modelling and the ability to interpret and communicate results. Lessons learned from country experiences using costing and cost-effectiveness to allocate funding towards efficient testing strategies will be shared. Lastly, participants will increase their ability to synthesize costing and cost-effectiveness data to inform development and implementation of high-impact HIV testing in Low- and Middle-Income Countries (LMICs).

## Welcome and introductions

*C.Case Johnson, World Health Organization, Switzerland;  
V.Cambiano, University College London, United Kingdom*

**Country panel: Discuss the challenges, issues and questions when considering cost-effectiveness, prioritizing and selecting HIV testing approaches**

*D.Long, Viet Nam Authority of HIV/AIDS Control, Vietnam; C.Case Johnson, World Health Organization, Switzerland; V.Cambiano, University College London, United Kingdom; P.Gaspar, Ministry of Health of Brazil, Brazil; M.Mugambi, MOH, Kenya*

**Costing and cost-effectiveness principles for HTS overview**

*F.Terris-Prestholt, London School of Hygiene and Tropical Medicine, United Kingdom; H.Maheswaran, University Of Warwick/ Malawi-Liverpool Wellcome Trust Clinical Research Programme, United Kingdom; P.Aylward, PSI, United States*

**Questions and answers**

*P.Aylward, PSI, United States*

**How cost effectiveness modelling was used to inform South African HIV testing policy**

*G.Meyer-Rath, Boston University, South Africa; T.Chidarikire, National Department of Health, South Africa*

**Questions and answers**

*B.Msminaga-Radebe, WHO, South Africa; A.Phillips, University College London, United Kingdom*

**Simulation activity: Building a cost-effective HIV testing programme**

*S.McGovern, Clinton Health Access Initiative, United States; C.Case Johnson, World Health Organization, Switzerland*

**Group discussions**

*F.Terris-Prestholt, London School of Hygiene and Tropical Medicine, United Kingdom; H.Maheswaran, University Of Warwick/ Malawi-Liverpool Wellcome Trust Clinical Research Programme, United Kingdom*

**Follow-up planning and closing remarks**

*C.Case Johnson, World Health Organization, Switzerland; V.Cambiano, University College London, United Kingdom*

**WEWS04 Doing no harm: Practical approaches for safely delivering HIV services with and for key populations**

Community Workshop

**Venue:** E105-108

**Time:** 14:30-17:00

**Level:** Intermediate

**Target audience:** Programme implementation specialist, Activist, General healthcare / Social services provider

**Seating limit:** 390

**Co-Facilitators:** Robyn Dayton, FHI 360, United States  
Greg Denham, Law Enforcement and HIV Network, Australia  
Revati Chawla, The International HIV/AIDS Alliance, United Kingdom  
Clinton Trout, Heartland Alliance International, United States  
Gavin Reid, Global Fund, Switzerland  
Beyonce Karungi, Trans Equality Uganda, Uganda

The workshop aims to have the audience understand common safety and security challenges that key populations HIV programmes face in hostile environments and their impacts on organizations, individuals, and programme outcomes. Participants will assess their organization's approach to safety and security, identifying gaps, and develop a plan to fill those gaps using multiple strategies, including: safety and security trainings, collaborations with law enforcement, and advocating with donors for increased safety and security investment.

**Workshop overview**

*R.Dayton, FHI 360, United States; G.Reid, Global Fund, Switzerland*

**Testimonials describing common security challenges and their impacts on small CBOs implementing HIV programs for key populations**

*L.van der Merwe, S.H.E Feminist Collective of Transgender Women in Africa, South Africa*

**Short presentation and small group work: Assessing organizations' current activities to keep staff and workplaces safe and secure**

*R.Chawla, The International HIV/AIDS Alliance, United Kingdom*

**Mini training sessions**

*C.Trout, Heartland Alliance International, United States; B.Nibogora, African Men for Sexual Health and Rights (AMShE), South Africa; M.French, Synergia - Initiatives for Human Rights, United States; N.Thomson, Law Enforcement and HIV Network (LEAHN), United States; P.Umoh, Heartland Alliance International, Nigeria; T.Jaiyebo, Heartland Alliance International, Nigeria; O.Tewobola Olufunke, Heartland Alliance International, Nigeria; A.Ambeau, Heartland Alliance International, Cote D'Ivoire*

**Closing remarks**

*R.Dayton, FHI 360, United States*

**WEWS05 NIH grantsmanship strategies and peer review workshop**

Community Workshop

**Venue:** G102-103

**Time:** 14:30-16:00

**Level:** Foundation

**Target audience:** Biology and pathogenesis scientist / Basic science researcher, Post-doctoral student, Administrator

**Seating limit:** 300

**Co-Facilitators:** Hortencia Hornbeak, NIH/NIAID, United States  
Dharmendar Rathore, NIH/NIAID, United States  
Peter Jackson, NIH/NIAID, United States  
Robert Unfer, NIH/NIAID, United States  
Paula Strickland, NIH/NIAID, United States  
Nancy Vazquez-Maldonado, NIH/NIAID, United States  
Ellen Buczko, NIH/NIAID, United States  
Chelsea Boyd, NIH/NIAID, United States  
Christopher Gordon, National Institute of Mental Health (NIMH), United States

In this workshop, experienced NIH staff will discuss strategies for developing a sustained, collaborative research grant portfolio. Topics will include: how to identify NIH funding opportunities; application development and submission; obtaining research resources; establishing strong research collaborations and surviving the rigorous peer review process. Processes for identifying already-supported research will be provided in order to avoid duplication and to identify potential collaborators. Importantly, attendees will learn who to contact for advice about any aspect of the NIH grant process.

**Introduction**

*H.Hornbeak, NIH/NIAID, United States*

**Strategies for success: Developing interdisciplinary scientific teams**

*P.Jackson, NIH/NIAID, United States*

**NIH international resources**

*P.Strickland, NIH/NIAID, United States*

**Overview of the peer review process**

*C.Boyd, NIH/NIAID, United States*

**Developing a grant application**

*N.Vazquez-Maldonado, NIH/NIAID, United States*

**Early career training opportunities**

*R.Unfer, NIH/NIAID, United States*

**Updates to policies**

*D.Rathore, NIH/NIAID, United States*

**Scientific priorities**

*C.Gordon, National Institute of Mental Health (NIMH), United States*

**Panel questions and answers**

*H.Hornbeak, NIH/NIAID, United States*

**WEWS06 In search of the fourth 90: Exploring and defining what quality of life means for communities and strategizing how we get there**

Community Workshop

**Venue:** G104-105

**Time:** 14:30-17:00

**Level:** Advanced

**Target audience:** Activist, Policy-maker, General healthcare / Social services provider

**Seating limit:** 277

**Co-Facilitators:** Kevin Moody, Kevin Moody Consulting, Netherlands  
Julian Vincent Hows, DRAG: Development Research Advocacy Governance, Netherlands  
Maryam Said, Sørlandet Hospital Kristiansand, Norway  
Stephen Doughty, Member of Parliament for Cardiff South and Penarth, United Kingdom  
Visvanathan Arumugam, India HIV/AIDS Alliance, India  
Flavian Rhode, Positive Vibes Trust, South Africa  
Paula Munderi, MRC/UVRI Uganda Research Unit on AIDS, Uganda

This session explores aspects of quality of life for people living with HIV, including: descriptions of innovative programmes; barriers to implementing person-centred approaches; identification of the medical/community interface; strategies to develop SMART indicators and/or a theory of change model for the fourth 90: quality of life; and next steps. The session will be facilitated by a diverse group of facilitators with expertise in people living with HIV issues, key populations, fast-track cities and person-centred, user-driven care from national, regional and international settings.

#### Welcome and introductory comments

*S. Doughty, Member of Parliament for Cardiff South and Penarth, United Kingdom*

#### Setting the stage – context

*K. Moody, Kevin Moody Consulting, Netherlands*

#### Innovative approaches to person-centred care

*M. Said, Sørlandet Hospital Kristiansand, Norway*

#### Non-health-related quality of life

*V. Arumugam, India HIV/AIDS Alliance, India*

#### Key populations

*F. Rhode, Positive Vibes Trust, South Africa*

#### Measurement

*P. Munderi, MRC/UVRI Uganda Research Unit on AIDS, Uganda*

#### Questions for clarification

*S. Doughty, Member of Parliament for Cardiff South and Penarth, United Kingdom*

#### Break into groups

*J. Hows, DRAG: Development Research Advocacy Governance, Netherlands*

#### Work in breakouts

#### Summary of conclusions

*K. Moody, Kevin Moody Consulting, Netherlands*

#### Closing

*S. Doughty, Member of Parliament for Cardiff South and Penarth, United Kingdom*

**WEWS08 Effective community engagement: How communities and health facilities can jointly improve eMTCT and paediatric HIV service delivery**

Community Workshop

**Venue:** Emerald Room

**Time:** 14:30-17:00

**Level:** Intermediate

**Target audience:** Community health worker, General healthcare / Social services provider, Policy-maker

**Seating limit:** 266

**Co-Facilitators:** Dominic Kemp, ViiV Healthcare, United Kingdom  
Doortje 't Hart, Aidsfonds, Netherlands  
Jacquelyne Alesi, Friends of Canon Gideon Foundation, Uganda  
Agnes Ronan, Pediatric-Adolescent Treatment Africa (PATA), South Africa

To reach all children for HIV prevention and care, collaboration between communities and healthcare facilities is essential. But, how is this done and how can it be improved? This interactive workshop, jointly run by Positive Action for Children's Fund (PACF), Paediatric-Adolescent-Treatment Africa (PATA), Aidsfonds and the Coalition for Children Affected by AIDS, will bring together healthcare workers, policy makers and community groups to learn and share practical experiences on how to effectively work together to improve eMTCT and paediatric HIV service delivery.

#### Welcome and introduction

*D. Kemp, ViiV Healthcare, United Kingdom*

#### Participants experience sharing

*D. 't Hart, Aidsfonds, Netherlands*

#### The perspective of a mother

*J. Alesi, Friends of Canon Gideon Foundation, Uganda*

#### Introduction to Clinic-Community Collaboration methodology

*H. Chorlton, PATA, South Africa*

#### A community intervention model for reaching all children exposed to HIV: Experiences and lessons from the TAFU programme in Uganda

*M. Musunguzi, Towards An Aids Free Generation Programme in Uganda, Uganda*

#### How to set up a community intervention programme? / How to initiate healthcare facility-community partnerships?

#### The way forward: What are our next steps?

#### Evaluation and closing statement

*A. Ronan, Pediatric-Adolescent Treatment Africa (PATA), South Africa*

**WEAD03 Treatment politics and financing in 2018**

Oral Abstract Session

**Venue:** Elicium 2

**Time:** 16:30-18:00

**Co-Chairs:** Mitchell Warren, AVAC, United States  
Vuyiseka Dubula-Majola, Stellenbosch University, South Africa

#### A political economy of HIV treatment policy: Drivers of health policy diffusion

*M. Kavanagh, S. Gupta, K. Parish, United States*

#### Using TRIPS-flexibilities as a leverage to improve access to HIV and hepatitis C medicines in Ukraine

*S. Kondratyuk, Ukraine*

#### America's \$10 billion overspend on sofosbuvir-based hepatitis C treatment resulting from unmerited patents

*A. Pattillo, J. Fortunak, D. Ravicher, M.H. Hughey, T. Amin, P. Radha Krishnel, United States*

#### Dolutegravir and the universal antiretroviral regimen: Good may be the enemy of perfect

*R. Granich, S. Gupta, L. Kosicki, B. Williams, M. Ruffner, United States*

## Review of national guidelines in 16 sub-Saharan African countries for inclusion of the adolescent HIV care continuum

*J. Kottutt, E. Rivadeneira, S. Hrapcak  
United States*

### WEAE05 I want you back: Improving retention on HIV programmes

Oral Abstract Session

**Venue:** Forum

**Time:** 16:30-18:00

**Co-Chairs:** Jean Nachega, Stellenbosch University, South Africa  
Gabriel Chamie, University of California, San Francisco, United States

### 10 years of Community ART Groups (CAG): Retention and viral load uptake in Tete, Mozambique

*L. Haldna, A. W. Torrens  
Belgium*

### Increasing retention in care through community systems strengthening: Lessons learned from 15 districts in South Africa

*M.R. Manganye, S. Berrada, A. Wagner, S. Gombarume, C. Wylie, A. Make  
South Africa*

### Same day ART initiation does not reduce 12-month retention among HIV-infected children in Uganda

*A. Kekitijwa, P. Elyanu, E. Nazziwa, G.P. Kisitu, R.N. Ssebunya, C. Katureebe, G. Namayanja, I. Lukabwe, E.N. Magongo, A. Namale, P.N. Ntege, M.R. Adler  
Uganda*

### Community patient tracking by Lay Community Health Workers (CHWs) is an effective strategy towards the 2nd & 3rd 90

*B.M. Morapedi, G. Morineau, C. Lesedi, J.M. Irige, B. Mantu, O. Sokwe, C. Pheko, K. Poloko  
Botswana*

### 'My best friends and my worst enemies':

### Understanding the roles of families in retaining South African adolescents living with HIV in care

*T.D. Ritchood, N. Ntlapo, M. Atujuna, S. Letoao, A. Oduru, L.G. Bekker  
United States*

### WEBS02 Why do we fail in responding to the epidemic among people who inject drugs?

Bridging Session

**Venue:** Hall 10

**Time:** 16:30-18:00

**Co-Chairs:** Julie Bates, Curtin University, Australia  
Frederick Altice, Yale University, United States

The world has failed in responding to the HIV epidemic among PWID. New infections increased by 33% between 2011 and 2015 – the UN goal was to reduce that number by 50% by 2015. This massive global failure of the AIDS response is particularly acute among PWID in EECA where lack of harm reduction and inappropriate strategies are driving the HIV epidemic and concomitant hepatitis and tuberculosis/MDR-TB epidemics. We will bring together the views of science, law enforcement and affected communities in a panel discussion moderated by two internationally recognized experts. We will devote significant time for debate and discussion with the audience. The moderator may also call on a Dutch representative in the audience to give a two-minute overview of the remarkable record of the Netherlands in eliminating new HIV infections among PWID.

#### Introduction

#### View from law enforcement

*N. Crofts, The University of Melbourne, Australia*

#### View from science

*M. Milloy, BC Centre on Substance Use, Canada*

#### View from impacted community

*A. Sarang, SKOSH, Netherlands*

## What about hepatitis and TB/MDR-TB: Why are we also failing PWID?

*N. Martin, University of California San Diego, United States*

### Debate between panellists and Q&A

#### Summary and concluding remarks

### WESY07 State of the ART

Symposia Session

**Venue:** Hall 12

**Time:** 16:30-18:00

**Co-Chairs:** Serge Eholie, University Teaching Hospital, Abidjan, Cote D'Ivoire  
Jenny Hoy, The Alfred Hospital and Monash University, Australia

This session will discuss the latest findings on ART, including treatment across the human lifespan (from newborns to elderly) and in special populations (including men who have sex with men, transgender, injection drug users, sex workers and migrants). It will consider: ART strategies for treatment and monitoring; new and investigational antiretroviral agents; ART-related adverse events, side effects and toxicities; adherence; and drug resistance.

#### Introduction

#### ART in Pregnancy

*L. Stranix, University of Zimbabwe, Zimbabwe*

#### Sequencing strategies in resource-limited countries

*L. Perez-Saleme, Hospital de Especialidades Centro Medico Nacional siglo XXI, Mexico*

#### New drug delivery systems

*K. Scarsi, College of Pharmacy, United States*

#### New antiretrovirals

*H. Stellbrink, University of Hamburg, Germany*

#### Lange/Van Tongeren Prizes (IAS/ANRS) for Young Investigators: Annual prizes

*P. Dabis, Director, ANRS, France; M. Heidenrijk, Joep Lange Institute, Netherlands; B. Crabtree Ramirez, ational Institute of Health Sciences and Nutrition, Salvador Zubirán (INCMNSZ), Mexico*

#### Closing remarks

### WESY08 'Nothing about us without us': Advancing human rights for key populations

Symposia Session

**Venue:** Auditorium

**Time:** 16:30-18:00

**Co-Chairs:** Judy Chang, International Network of People Who Use Drugs (INPUD), United Kingdom  
Monica Beg, United Nations Office On Drugs and Crime (UNODC), Austria

The session will focus on the current struggles and challenges of key and vulnerable populations in advancing human rights and legal reform agendas. Issues to be discussed include efforts to improve the legal and human rights environment and frameworks for better and equal access to HIV prevention and treatment. The session will cover: efforts to decriminalize and depenalize sex workers and people who use drugs; best practices of legal reform activism on the national and international levels; new challenges and new achievements in advancing the rights of lesbian, gay, bisexual, transgender, queer people, and men who have sex with men; challenges and opportunities for transgender people in the HIV response; rights of people in prisons and other closed settings; and improving the participation of young people in activism and advocacy work. The session will also discuss the new strategies that activist groups are applying in regions with shrinking spaces for civil society activism, such as the Eastern Europe and Central Asia region.

#### High Level Address

*L. Singh, Parliament of Australia, Australia*

#### Introduction

# Wednesday 25 July | Sessions



J.Chang, International Network of People Who Use Drugs (INPUD), United Kingdom; M.Beg, United Nations Office On Drugs and Crime (UNODC), Austria

## Addressing the challenge of human rights violations among sexual minorities in Eastern Europe and Central Asia

V.Djuma, The Eurasian Coalition on Male Health, (ECOM), Estonia

## Making prison reforms work holistically to effectively and appropriately address HIV

L.Mabote, AIDS and Rights Alliance for Southern Africa, South Africa

## Fighting for human rights and health of people who use drugs in the countries with shrinking space for civil society: The case of Russia

A.Kurmanaevskii, Russian Forum of People who Use Drugs, Russian Federation

## Sex work as work: Challenging policy and labour frameworks in advancing HIV and human rights

D.Ogutu, African Sex Workers Alliance (ASWA), Kenya; K.Buthelezi, SWEAT, South Africa

## Expanding trans participation in HIV activism

P.Brown-Acton, INA (Maori, Indigenous & South Pacific) HIV/AIDS Foundation, New Zealand

## Q&A

## Conclusion

### WESY10 Prioritized yet dying: Addressing the needs of children and adolescents living with HIV

Symposia Session

**Venue:** Elicium 1

**Time:** 16:30-18:00

**Co-Chairs:** Lucie Cluver, Oxford University, United Kingdom  
Sabrina Ern , AIDSfonds,

Approximately 2.1 million children under the age of 15 years are living with HIV. HIV is the second largest cause of adolescent deaths globally. Every day, 400 children acquire HIV, and every day, 330 children die. Although HIV should now be a manageable condition, fewer than half of the children needing treatment are receiving it. Unless we urgently change our approach towards children and adolescents, an AIDS-free generation will never be achieved. Looking at the continuum of care, from HIV testing and diagnosis, through retention, treatment, and viral suppression, this session will demonstrate the missed chances for HIV prevention and the opportunities for improving AIDS-free survival among children and adolescents across their lifetime.

#### Welcome and introduction

L.Cluver, Oxford University, United Kingdom

#### Opening address: why does this all matter?

K.Barrow Simplis, First Lady of Belize and Special Envoy for Women and Children, Belize

#### Perspective of children and adolescents living with HIV

Y.Panfilova, Teenergizer, Ukraine

#### Perspective of a mother

C.Banya, International Community of Women Living with HIV (ICW), Malawi

#### Perspective of a healthcare provider

T.Nkumane, Lobamba Clinic, Swaziland

#### Perspective of a professional who brings in policy perspective

D.Webb, United Nations Development Programme (UNDP), United States

#### Moderated discussion

#### Closing remarks

L.Cluver, Oxford University, United Kingdom

### WESY11

## Challenges and Controversies to Accelerating Toward Epidemic Control in PEPFAR-supported Countries: Perception vs. Data

Symposia Session

**Venue:** Hall 11A

**Time:** 16:30-18:00

**Chair:** Mark Harrington, ,

By 2020, as many as 13 high-burden countries will be poised to achieve HIV epidemic control due to PEPFAR support. However, there are critical programmatic and policy challenges and controversies that threaten progress in the 50+ countries that benefit from the PEPFAR program.

This symposium will showcase varying perspectives on some of the key challenges and controversies in achieving epidemic control. The panelists will discuss how these developments affect key policy decisions, demonstrate how these developments relate to specific program implementation activities, and clarify how PEPFAR-supported programs navigate these challenges by weighing the best available evidence and the importance of evidence-driven policy making. The program will feature key scientific, program and policy leaders from a range of perspectives.

#### Introduction

#### Dolutegravir and Neural Tube Defects (NTDs)

C.Moore, Centers for Disease Control and Prevention (CDC), United States; A.Phillips, University College London, United Kingdom

#### Accelerating ART scale-up: SEARCH vs. BCPP

J.Moore, Centers for Disease Control and Prevention (CDC), United States; M.Petersen, University of California, Berkeley, United States

#### Structural Barriers to Achieving Epidemic Control

I.Semini, UNAIDS, Switzerland

#### Open discussion

### WESY09 Eliminating HIV latency: Shock and kill or block and lock?

Symposia Session

**Venue:** Hall 11B

**Time:** 16:30-18:00

**Co-Chairs:** Petronela Ancuta, Universite de Montreal and CHUM Research Centre, Canada  
Zhiwei Chen, The University of Hong Kong, Hong Kong

The major barrier to a cure for HIV or long-term remission off Antiretroviral therapy (ART) is the persistence of latently infected cells. Persistence occurs because of infection of long-lived cells or through clonal expansion of infected cells. Understanding how HIV persists is critical to developing new strategies for elimination. These include strategies to reverse latency through activation to allow for immune recognition. Alternative approaches include permanent silencing of HIV expression through inhibitors of mammalian target of rapamycin (mTOR) function or gene silencing approaches.

#### Introduction

#### Introductory comments

M.Goodenow, NIH Office of AIDS Research, United States

#### Understanding HIV persistence – do defective viruses matter?

Y.Ho, Yale University School of Medicine, United States

#### Low level transcription on ART – implications for latency elimination

S.Yuki, University of California, United States

#### TLR agonists and latency reversal: can they both shock and kill?

M.Tolstrup, Aarhus University, Denmark

#### Block and lock using gene silencing

A.Kelleher, The University of New South Wales (UNSW), Australia

## Understanding community participation in cure studies: what scientists need to know

C.Martinez, NAPWHA, Australia

### Wrap-up

#### **WEWS09 Improving patient care through better management of HIV drug drug interactions: An interactive case workshop exploring key clinical challenges in both Sub-Saharan Africa and Europe**

Science Workshop

**Venue:** G102-103

**Time:** 16:30-18:00

**Level:** Intermediate

**Target audience:** Physician, Pharmacist, General healthcare / Social services provider

**Seating limit:** 300

Drug drug interactions (DDIs) remain a vital consideration for people living with HIV and the healthcare professionals who treat them. This session will: discuss strategies for managing complex clinical scenarios through facilitated discussion and engagement with three interactive patient cases; develop skills in clinical decision making, including exploring the resources available to assist with DDI management; and improve future clinical decision making and, thereby, patient care.

#### Introduction

D.Burger, Radboud University Medical Center, Netherlands;  
D.Back, University of Liverpool, United Kingdom

#### Basic principles of Drug-drug Interactions with antiretrovirals

D.Back, University of Liverpool, United Kingdom

#### Antiretrovirals and Drug-drug interactions in pregnancy

A.Colbers, Radboudumc, Netherlands

#### Drug-drug Interactions and transgender women living with HIV

M.Boffito, Chelsea and Westminster Hospital, United Kingdom

#### Polypharmacy and Drug-drug Interactions in an ageing population

C.Marzolini, University Hospital of Basel and University of Basel, Switzerland

#### Multiple comorbidity in a Sub-Saharan African context

C.Waitt, Infectious Diseases Institute, Uganda

#### **WEWS10 Self-care and prevention of burnout among activists: Tools for everyday life**

Public Workshop

**Venue:** GV Session Room 1

**Time:** 16:30-18:00

The current era requires activists to be effective in mobilizing a global response to AIDS within the broader context of SDGs and the specific challenges of national political contexts. Challenging personal experiences, limited financial resources, competing priorities and high workload put a lot of pressure on activists. If they do not navigate these carefully, activists are at high risk of burnout. We will discuss and share with participants a range of tools for prevention of burnout and self-care for the activists. Participants will be able to pick and choose tools that speak to their individual needs and interests.

#### Introductory remarks

S.Mellors, International HIV/AIDS Alliance, United Kingdom;  
G.Dovbakh, Eurasian Harm Reduction Association (EHRA), Lithuania

#### Participants' personal work

#### Panel discussion: Preventing and overcoming burnout

V.Dubula-Majola, Stellenbosch University, South Africa; A.Aher, IRGT, a Global Network of Transgender Women and HIV, India; B.Kasaha, Positively UK and Global Network of People Living with HIV, United Kingdom

### Questions and answers with the audience

#### Group work and reporting back

#### Conclusions from facilitators

#### Closing: Participants' personal work

#### Regional Members' Meeting for Asia and the Pacific Islands

Regional Session

**Venue:** E105-108

**Time:** 17:15-18:15

**Co-Chairs:** Nittaya Phanuphak, Thai Red Cross AIDS Research Centre, Thailand  
Sharon Lewin, The Doherty Institute, The University of Melbourne, Australia  
Roy Chan, National Skin Centre, Singapore  
Shuzo Matsushita, Kumamoto University,

#### Introduction: a year in the IAS (summary of programmes and activities developed over the past year and membership numbers)

#### IAS Educational Fund meetings in Bangkok, Thailand and Tokyo, Japan

#### The Research-for-Cure Academy and Advocacy-for-Cure Academy

#### Membership engagement